Can Pharmacologic Agents Slow Abdominal Aortic Aneurysm Growth?

Seminars in Vascular Surgery

Volumn 25, Issue 1, 2012, Pages 25-28

  Samson, Russell ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA TOCOPHEROL; AMFEBUTAMONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CROMOGLYCATE DISODIUM; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOXYCYCLINE; ESTROGEN; GELATINASE A; GELATINASE B; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; L SELECTIN; PLACEBO; PROPRANOLOL; RAPAMYCIN; ROXITHROMYCIN; THIAZIDE DIURETIC AGENT; TRANILAST; VARENICLINE;

ABDOMINAL AORTA ANEURYSM; ARTICLE; CELL INFILTRATION; CHLAMYDIASIS; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; ESOPHAGUS IRRITATION; GASTROINTESTINAL IRRITATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LYMPHOCYTE; MACROPHAGE; MAST CELL; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SEX DIFFERENCE; SIDE EFFECT; SKIN SENSITIVITY; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE;

ANIMALS; AORTIC ANEURYSM, ABDOMINAL; CARDIOVASCULAR AGENTS; DISEASE PROGRESSION; HUMANS; TREATMENT OUTCOME;

EID: 84861011508     PISSN: 08957967     EISSN: 15584518     Source Type: Journal    
DOI: 10.1053/j.semvascsurg.2012.03.004     Document Type: Article

References (46)

1. Golledge J., Muller J., Daugherty A., et al. Abdominal aortic aneurysm: pathogenesis and implications for management. Arterioscler Thromb Vasc Biol 2006, 26:2605-2613.
2. Miyake T., Morishita R. Pharmacological treatment of abdominal aortic aneurysm. Cardiovasc Res 2009, 83:436-443.
3. Lederle F.A., Johnson G.R., Wilson S.E., et al. Prevalence and associations of abdominal aortic aneurysm detected through screening. Aneurysm Detection and Management (ADAM) Veterans Affairs Cooperative Study Group. Ann Intern Med 1997, 126:441-449.
4. Freestone T., Turner R.J., Coady A., et al. Inflammation and matrix metalloproteinases in the enlarging abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1995, 15:1145-1151.
5. Tchougounova E., Lundequist A., Fajardo I., et al. A key role for mast cell chymase in the activation of pro-matrix metalloprotease-9 and pro-matrix metalloprotease-2. J Biol Chem 2005, 280:9291-9296.
6. Sun J., Sukhova G.K., Yang M., et al. Mast cells modulate the pathogenesis of elastase-induced abdominal aortic aneurysms in mice. J Clin Invest 2007, 117:3359-3368.
7. Nakae S., Suto H., Kakurai M., et al. Mast cells enhance T cell activation: importance of mast cell-derived TNF. Proc Natl Acad Sci U S A 2005, 102:6467-6472.
8. Lindholt J.S., Juul S., Vammen S., et al. Immunoglobulin A antibodies against Chlamydia pneumoniae are associated with expansion of abdominal aortic aneurysm. Br J Surg 1999, 86:634-638.
9. Saraff K., Babamusta F., Cassis L.A., et al. Aortic dissection precedes formation of aneurysms and atherosclerosis in angiotensin II-infused, apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003, 23:1621-1626.
10. Schonbeck U., Sukhova G.K., Gerdes N., et al. T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. Am J Pathol 2002, 161:499-506.
11. Goodall S., Crowther M., Hemingway D.M., et al. Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation 2001, 104:304-309.
12. McMillan W.D., Tamarina N.A., Cipollone M., et al. Size matters: the relationship between MMP-9 expression and aortic diameter. Circulation 1997, 96:2228-2232.
13. Petersen E., Gineitis A., Wagberg F., et al. Activity of matrix metalloproteinase-2 and -9 in abdominal aortic aneurysms. Relation to size and rupture. Eur J Vasc Endovasc Surg 2000, 20:457-461.
14. Tamarina N.A., McMillan W.D., Shively V.P., et al. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 1997, 122:264-271. discussion 271-272.
15. Defawe O.D., Colige A., Lambert C.A., et al. TIMP-2 and PAI-1 mRNA levels are lower in aneurysmal as compared to athero-occlusive abdominal aortas. Cardiovasc Res 2003, 60:205-213.
16. Miller F.J., Sharp W.J., Fang X., et al. Oxidative stress in human abdominal aortic aneurysms: a potential mediator of aneurysmal remodeling. Arterioscler Thromb Vasc Biol 2002, 22:560-565.
17. Bergqvist D. Pharmacological interventions to attenuate the expansion of abdominal aortic aneurysm (AAA)-asystematic review. Eur J Vasc Endovasc Surg 2011, 41:663-667.
18. Lederle F.A., Nelson D.B., Joseph A.M. Smokers' relative risk for aortic aneurysm compared with other smoking-related diseases: a systematic review. J Vasc Surg 2003, 38:329-334.
19. Brady A.R., Thompson S.G., Fowkes F.G., et al. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 2004, 110:16-21.
20. Hackam D.G., Thiruchelvam D., Redelmeier D.A. Angiotensin-converting enzyme inhibitors and aortic rupture: a population-based case-control study. Lancet 2006, 368:659-665.
21. Liao S., Miralles M., Kelley B.J., et al. Suppression of experimental abdominal aortic aneurysms in the rat by treatment with angiotensin-converting enzyme inhibitors. J Vasc Surg 2001, 33:1057-1064.
22. Daugherty A., Manning M.W., Cassis L.A. Antagonism of AT2 receptors augments angiotensin II-induced abdominal aortic aneurysms and atherosclerosis. Br J Pharmacol 2001, 134:865-870.
23. Propranolol for small abdominal aortic aneurysms: results of a randomized trial. J Vasc Surg 2002, 35:72-79. Propanolol Aneurysm Trial I.
24. Vammen S., Lindholt J.S., Ostergaard L., et al. Randomized double-blind controlled trial of roxithromycin for prevention of abdominal aortic aneurysm expansion. Br J Surg 2001, 88:1066-1072.
25. Lawrence D.M., Singh R.S., Franklin D.P., et al. Rapamycin suppresses experimental aortic aneurysm growth. J Vasc Surg 2004, 40:334-338.
26. Mosorin M., Juvonen J., Biancari F., et al. Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study. J Vasc Surg 2001, 34:606-610.
27. Abdul-Hussien H., Hanemaaijer R., Verheijen J.H., et al. Doxycycline therapy for abdominal aneurysm: improved proteolytic balance through reduced neutrophil content. J Vasc Surg 2009, 49:741-749.
28. Holmes D.R., Wester W., Thompson R.W., et al. Prostaglandin E2 synthesis and cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 1997, 25:810-815.
29. Walton L.J., Franklin I.J., Bayston T., et al. Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms. Circulation 1999, 100:48-54.
30. King V.L., Trivedi D.B., Gitlin J.M., et al. Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice. Arterioscler Thromb Vasc Biol 2006, 26:1137-1143.
31. Gitlin J.M., Trivedi D.B., Langenbach R., et al. Genetic deficiency of cyclooxygenase-2 attenuates abdominal aortic aneurysm formation in mice. Cardiovasc Res 2007, 73:227-236.
32. Parodi F.E., Mao D., Ennis T.L., et al. Oral administration of diferuloylmethane (curcumin) suppresses proinflammatory cytokines and destructive connective tissue remodeling in experimental abdominal aortic aneurysms. Ann Vasc Surg 2006, 20:360-368.
33. Tsuruda T., Kato J., Hatakeyama K., et al. Adventitial mast cells contribute to pathogenesis in the progression of abdominal aortic aneurysm. Circ Res 2008, 102:1368-1377.
34. Gavrila D., Li W.G., McCormick M.L., et al. Vitamin E inhibits abdominal aortic aneurysm formation in angiotensin II-infused apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005, 25:1671-1677.
35. Ailawadi G., Eliason J.L., Roelofs K.J., et al. Gender differences in experimental aortic aneurysm formation. Arterioscler Thromb Vasc Biol 2004, 24:2116-2122.
36. Martin-McNulty B., Tham D.M., da Cunha V., et al. 17 Beta-estradiol attenuates development of angiotensin II-induced aortic abdominal aneurysm in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2003, 23:1627-1632.
37. Grigoryants V., Hannawa K.K., Pearce C.G., et al. Tamoxifen up-regulates catalase production, inhibits vessel wall neutrophil infiltration, and attenuates development of experimental abdominal aortic aneurysms. J Vasc Surg 2005, 41:108-114.
38. Steinmetz E.F., Buckley C., Shames M.L., et al. Treatment with simvastatin suppresses the development of experimental abdominal aortic aneurysms in normal and hypercholesterolemic mice. Ann Surg 2005, 241:92-101.
39. Sukhija R., Aronow W.S., Sandhu R., et al. Mortality and size of abdominal aortic aneurysm at long-term follow-up of patients not treated surgically and treated with and without statins. Am J Cardiol 2006, 97:279-280.
40. Schouten O., van Laanen J.H., Boersma E., et al. Statins are associated with a reduced infrarenal abdominal aortic aneurysm growth. Eur J Vasc Endovasc Surg 2006, 32:21-26.
41. Hurks R., Hoefer I.E., Vink A., et al. Different effects of commonly prescribed statins on abdominal aortic aneurysm wall biology. Eur J Vasc Endovasc Surg 2010, 39:569-576.
42. Kalyanasundaram A., Elmore J.R., Manazer J.R., et al. Simvastatin suppresses experimental aortic aneurysm expansion. J Vasc Surg 2006, 43:117-124.
43. Shiraya S., Miyake T., Aoki M., et al. Inhibition of development of experimental aortic abdominal aneurysm in rat model by atorvastatin through inhibition of macrophage migration. Atherosclerosis 2009, 202:34-40.
44. Nagashima H., Aoka Y., Sakomura Y., et al. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppresses production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002, 36:158-163.
45. Ferguson C.D., Clancy P., Bourke B., et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J 2010, 159:307-313.
46. Takagi H., Manabe H., Umemoto T. A meta-analysis of association between serum lipoproteins and abdominal aortic aneurysm. Am J Cardiol 2010, 106:753-754.